Drugs in development for the treatment of chronic hepatitis B

被引：4
作者：
Simone I. Strasser
机构：
[1] AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Missenden Rd.
来源：
Current Hepatitis Reports | 2012年 / 11卷 / 2期
关键词：
Bay; 41-4109; Clevudine; Emtricitabine; Entecavir; GS; 9620; Hepatitis B; Interferon; Myrcludex-B; Nitazoxanide; Novel therapies; Prodrug; REP; 9; AC; Tenofovir;
D O I：
10.1007/s11901-012-0131-9
中图分类号：
学科分类号：
摘要：
Currently available therapies for patients with chronic hepatitis B are safe, well tolerated, and highly effective in achieving improved outcomes reflecting potent viral suppression with low rates of antiviral resistance. For the majority of patients however, long-term treatment is necessary with significant cost implications and potential for complications. Current oral antiviral therapies are directed only at a single component of the hepatitis B lifecycle, while interferon therapy is effective only in a minority of patients. Efforts are underway to develop agents directed at novel targets derived from mechanisms of cellular entry, viral replication, or viral assembly leading to preclinical and clinical trials with impressive preliminary results. Additional development of agents directed at the host immune response offers the possibility of combination therapies with independent mechanisms of action that may pave the way for regimens of finite duration with long-lasting control of chronic hepatitis B infection. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码：111 / 118
页数：7
相关论文
共 58 条
[21]  
Seok J.I., Lee D.K., Lee C.H., Et al., Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA, Hepatology, 49, pp. 2080-2086, (2009)
[22]  
Tak W.Y., Park S.Y., Jung M.K., Et al., Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients, Hepatol Res, 39, pp. 944-947, (2009)
[23]  
Kim B.K., Oh J., Kwon S.Y., Choe W.H., Ko S.Y., Rhee K.H., Et al., Clevudine myopathy in patients with chronic hepatitis B, J Hepatol, 51, pp. 829-834, (2009)
[24]  
Kim H.J., Park D.I., Park J.H., Et al., Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B, Liver Int, 30, pp. 834-840, (2010)
[25]  
Tak W.Y., Park S.Y., Cho C.M., Et al., Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy, J Hepatol, 53, pp. 261-266, (2010)
[26]  
Berg T., Marcellin P., Zoulim F., Et al., Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronichepatitis B virus infection, Gastroenterology, 139, 4, pp. 1207-1217, (2010)
[27]  
Patterson S.J., George J., Strasser S.I., Et al., Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B, Gut, 60, pp. 247-254, (2011)
[28]  
Si-Ahmed S.N., Pradat P., Zoutendijk R., Et al., Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study, Antiviral Res, 92, pp. 90-95, (2011)
[29]  
Liaw Y.F., Sheen I.S., Lee C.M., Et al., Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, Hepatology, 53, pp. 62-72, (2011)
[30]  
Fung J., Lai C.L., Yuen M.F., LB80380: A promising new drug for the treatment of chronic hepatitis B, Expert Opin Investig Drugs, 17, pp. 1581-1588, (2008)
123456